Chronic Lymphocytic Leukemia Update, Issue 1, 2019 — Part 1: Our
most recent one-on-one interview with Dr Wierda featuring emerging
research and cases from his practice:
Evolution of the treatment paradigm for patients with chronic
lymphocytic leukemia (CLL) (00:00)
Biomarker assessment for patients with newly diagnosed CLL
(03:27)
Therapeutic approach for older patients with CLL; IGHV mutation
status in treatment decision-making (06:41)
Case: A woman in her early 70s with CLL with
deletion 17p, a p53 mutation and no IGHV mutation achieves a
complete remission with ibrutinib and venetoclax as first-line
therapy on a clinical trial (10:40)
Implications of del(17p) and p53 mutations in CLL pathogenesis
and for the selection of treatment (12:03)
Efficacy of venetoclax alone and in combination with
obinutuzumab or rituximab (15:40)
Phase II trial of ibrutinib with venetoclax for CLL
(20:04)
Ongoing Phase II CAPTIVATE trial of ibrutinib with venetoclax
as front-line therapy (22:20)
Relevance of minimal residual disease (MRD) as a clinical
endpoint in CLL (24:54)
Effect of MRD status on outcomes in the Phase III MURANO trial
evaluating venetoclax with rituximab for relapsed/refractory CLL
(28:02)
Risk of tumor lysis syndrome (TLS) with venetoclax (32:02)
Prophylactic approaches for TLS associated with venetoclax
(35:00)
Ongoing Phase III trial of ibrutinib and venetoclax; evaluation
of ibrutinib/venetoclax in combination with an anti-CD20 antibody
(37:02)
Potential clinical role of ibrutinib/venetoclax for patients
with CLL (41:27)
Case: A man in his late 50s with idiopathic
thrombocytopenic purpura and del(11q) CLL with no IGHV mutation
receives acalabrutinib after multiple lines of therapy, including
venetoclax and ibrutinib (43:23)
Efficacy and side-effect profile of acalabrutinib versus
ibrutinib (48:39)
Results of the Phase III ASCEND study of acalabrutinib alone
versus investigator’s choice of idelalisib/rituximab or
bendamustine/rituximab for relapsed/refractory CLL (54:34)
Ongoing Phase III ELEVATE-TN trial of acalabrutinib alone
versus acalabrutinib/obinutuzumab versus chlorambucil/obinutuzumab
for previously untreated CLL (56:14)
Emerging data with next-generation, reversible Bruton tyrosine
kinase inhibitors for CLL (1:00:34)
Mechanism of action, efficacy and tolerability of the recently
FDA-approved antibody-drug conjugate moxetumomab pasudotox-tdfk for
relapsed/refractory hairy cell leukemia (1:02:24)
Case: A woman in her early 60s with del(17p)
CLL and no IGHV mutation receives venetoclax and obinutuzumab as
first-line therapy (1:05:51)
Activity and safety profile of chimeric antigen receptor (CAR)
T-cell therapy for CLL (1:08:40)
Challenges in the clinical management of CLL (1:13:29)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.